Investigation Report on China Alendronate Sodium Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333631|
|出版日期||內容資訊||英文 30 Pages
|中國的阿崙膦酸鈉市場分析 Investigation Report on China Alendronate Sodium Market, 2010-2019|
|出版日期: 2015年06月25日||內容資訊: 英文 30 Pages||
China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among elders is over 50%, among which nearly 33% suffer from fracture. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020. Hence osteoporosis drugs' promising future.
Alendronate sodium is one of the osteoporosis drugs with the longest history of application. And it is the first diphosphonate that got FDA's approval to be used for the treatment of postmenopausal osteoporosis and the first drug approved by FDA to treat osteoporosis in men.
By various mechanisms of action, alendronate sodium can enhance bone strength, alleviate and prevent osteoporosis, effectively reduce the risk of fracture in centrum, hip bone and other parts. It is also the only drug that can effectively reduce the risk in various parts of the body especially in hip.
Alendronate sodium develops fast after entering China, annual sales value rising from less than CNY 30 million in 2005 to CNY 121 million in 2014 and CAGR during this period reaching 18.14%. Merck Sharp & Dohme (Italy), CSPC Ouyi Pharmaceutical Co., Ltd, Beijing Wansheng Pharmaceutical Co., Ltd, Haini Pharmaceutical Co., Ltd and Chengdu Tiantaishan Pharmaceutical Co., Ltd occupy the majority of market share, among which Merck Sharp & Dohme (Italy) has the largest market share of nearly 90% for sales value in 2014.
The ageing population in China keeps growing, people aged 60 and above amounting to 212.42 million and occupying 15.5% of the total population while people aged 65 and above amounting to 137.55 million and occupying 10.1% of the total population by the end of 2014. With the ageing population, the incidence and number of cases of osteoporosis will continue to grow. Therefore the market size of alendronate sodium is expected to keep expanding in the next few years in China.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: